Sequence- and structural-selective nucleic acid binding revealed by the melting of mixtures

Nucleic Acids Research

Volumn 34, Issue 2, 2006, Pages 1-7

  Shi, Xiaochun ^a   Chaires, Jonathan B ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CONGOCIDINE; DACTINOMYCIN; DAUNORUBICIN; DNA; ETHIDIUM; NUCLEIC ACID; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; POLYNUCLEOTIDE; RNA; UNCLASSIFIED DRUG; WP 631; DRUG DERIVATIVE; LIGAND; OLIGODEOXYRIBONUCLEOTIDE;

ARTICLE; CONTROLLED STUDY; DENATURATION; DNA RNA HYBRIDIZATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; GENE TARGETING; GENETIC SCREENING; LIGAND BINDING; MELTING POINT; NUCLEIC ACID STRUCTURE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPECTROPHOTOMETRY; THERMAL ANALYSIS; CHEMISTRY; DNA DENATURATION; EVALUATION; GENETIC PROCEDURES; METABOLISM; TEMPERATURE;

BASE SEQUENCE; DAUNORUBICIN; GENETIC TECHNIQUES; LIGANDS; NUCLEIC ACID DENATURATION; NUCLEIC ACIDS; OLIGODEOXYRIBONUCLEOTIDES; POLYNUCLEOTIDES; TEMPERATURE;

EID: 32644448247     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gnj012     Document Type: Article

References (46)

1. Hurley,L.H. (2001) Secondary DNA structures as molecular targets for cancer therapeutics. Biochem. Soc. Trans., 29, 692-696.
2. Hurley,L.H. (2002) DNA and its associated processes as targets for cancer therapy. Nature Rev. Cancer, 2, 188-200.
3. Mergny,J.L. and Helene,C. (1998) G-quadraplex DNA: A target for drug design. Nature Medicine, 4, 1366-1367.
4. Neidle,S. and Thurston,D.E. (2005) Chemical approaches to the discovery and development of cancer therapies. Nature Rev. Cancer, 5, 285-296.
5. Darnell,J.E.,Jr (2002) Transcription factors as targets for cancer therapy. Nature Rev. Cancer, 2, 740-749.
6. Dervan,P.B. (2001) Molecular recognition of DNA by small molecules. Bioorg. Med. Chem., 9, 2215-2235.
7. Dervan,P.B. and Baker,B.F. (1986) Design of sequence-specific DNA cleaving molecules. Comparison of distamycin-EDTA X Fe(II) and N-bromoacetyldistamycin. Ann. NY Acad. Sci., 471, 51-59.
8. Dervan,P.B., Doss,R.M. and Marques,M.A. (2005) Programmable DNA binding oligomers for control of transcription. Curr. Med. Chem. Anti-Canc Agents, 5, 373-387.
9. Dervan,P.B. and Edelson,B.S. (2003) Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr. Opin. Struct. Biol., 13, 284-299.
10. Janowski,B.A., Kaihatsu,K., Huffman,K.E., Schwartz,J.C., Ram,R., Hardy,D., Mendelson,C.R. and Corey,D.R. (2005) Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. Nature Chem. Biol., 1, 210-215.
11. Qu,X., Trent,J.O., Fokt,I., Priebe,W. and Chaires,J.B. (2000) From the cover: Allosteric, chiral-selective drug binding to DNA. Proc. Natl Acad. Sci. USA, 97, 12032-12037.
12. Hurley,L.H., Wheelhouse,R.T., Sun,D., Kerwin,S.M., Salazar,M., Fedoroff,O.Y., Han,F.X., Han,H., Izbicka,E. and Von Hoff,D.D. (2000) G-quadruplexes as targets for drug design. Pharmacol. Ther., 85, 141-158.
13. Neidle,S. and Parkinson,G. (2002) Telomere maintenance as a target for anticancer drug discovery. Nature Rev. Drug Discov., 1, 383-393.
14. Grand,C.L., Han,H., Munoz,R.M., Weitman,S., Von Hoff,D.D., Hurley,L.H. and Bearss,D.J. (2002) The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol. Cancer Ther., 1, 565-573.
15. Kim,M.Y., Gleason-Guzman,M., Izbicka,E., Nishioka,D. and Hurley,L.H. (2003) The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res., 63, 3247-3256.
16. Seenisamy,J., Bashyam,S., Gokhale,V., Vankayalapati,H., Sun,D., Siddiqui-Jain,A., Streiner,N., Shin-Ya,K., White,E., Wilson,W.D. et al. (2005) Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J. Am. Chem. Soc., 127, 2944-2959.
17. Seenisamy,J., Rezler,E.M., Powell,T.J., Tye,D., Gokhale,V., Joshi,C.S., Siddiqui-Jain,A. and Hurley,L.H. (2004) The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J. Am. Chem. Soc., 126, 8702-8709.
18. Siddiqui-Jain,A., Grand,C.L., Bearss,D.J. and Hurley,L.H. (2002) Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl Acad. Sci. USA, 99, 11593-11598.
19. Lane,M.J., Dabrowiak,J.C. and Vournakis,J.N. (1983) Sequence specificity of actinomycin D and Netropsin binding to pBR322 DNA analyzed by protection from DNase I. Proc. Natl Acad. Sci. USA, 80, 3260-3264.
20. Low,C.M., Drew,H.R. and Waring,M.J. (1984) Sequence-specific binding of echinomycin to DNA: Evidence for conformational changes affecting flanking sequences. Nucleic Acids Res., 12, 4865-4879.
21. Van Dyke,M.W., Hertzberg,R.P. and Dervan,P.B. (1982) Map of distamycin, netropsin, and actinomycin binding sites on heterogeneous DNA: DNA cleavage-inhibition patterns with methidiumpropyl-EDTA.Fe(II). Proc. Natl Acad. Sci. USA, 79, 5470-5474.
22. Chaires,J.B. (1992) Application of Equilibrium Binding Methods to Elucidate the Sequence Specificity of Antibiotic Binding to DNA. In Hurley,L.H. (ed.), Advances in DNA Sequence Specific Agents. JAI Press, Inc., Greenwich, CT, Vol. 1, pp. 3-23.
23. Muller,W. and Crothers,D.M. (1975) Interactions of heteroaromatic compounds with nucleic acids. 1. The influence of heteroatoms and polarizability on the base specificity of intercalating ligands. Eur. J. Biochem., 54, 267-277.
24. Chaires,J.B. (2002) A Competition Dialysis Assay for the Study of Structure-Selective Ligand Binding to Nucleic Acids. In Beaucage,S.L., Bergstrom,D.E., Glick,G.D. and Jones,R.A. (eds.), Current Protocols in Nucleic Acid Chemistry. John Wiley & Sons, Inc., NY, Vol. 1, pp. 8.3.1-8.3.8.
25. Ren,J. and Chaires,J.B. (1999) Sequence and structural selectivity of nucleic acid binding ligands. Biochem., 38, 16067-16075.
26. Ren,J. and Chaires,J.B. (2001) Rapid screening of structurally selective ligand binding to nucleic acids. Methods Enzymol., 340, 99-108.
27. Chaires,J.B. (2005) Competition dialysis: An assay to measure the structural selectivity of drug-nucleic acid interactions. Curr. Med. Chem. Anti-Canc Agents, 5, 339-352.
28. Lazurkin,Y.S., Frank-Kamenetskii,M.D. and Trifonov,E.N. (1970) Melting of DNA: Its study and application as a research method. Biopolymers, 9, 1253-1306.
29. Crothers,D.M. (1971) Statistical thermodynamics of nucleic acid melting transitions with coupled binding equilibria. Biopolymers, 10, 2147-2160.
30. McGhee,J.D. (1976) Theoretical calculations of the helix-coil transition of DNA in the presence of large, cooperatively binding ligands. Biopolymers, 15, 1345-1375.
31. Wilson,W.D., Tanious,F.A., Fernandez-Saiz,M. and Rigl,C.T. (1997) Evaluation of drug-nucleic acid interactions by thermal melting curves. Methods Mol. Biol., 90, 219-240.
32. Leng,F., Priebe,W. and Chaires,J.B. (1998) Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. Biochemistry, 37, 1743-1753.
33. Darby,R.A., Sollogoub,M., McKeen,C., Brown,L., Risitano,A., Brown,N., Barton,C., Brown,T. and Fox,K.R. (2002) High throughput measurement of duplex, triplex and quadruplex melting curves using molecular beacons and a LightCycler. Nucleic Acids Res., 30, e39.
34. Fox,K.R. and Waring,M.J. (1987) Footprinting at low temperatures: evidence that ethidium and other simple intercalators can discriminate between different nucleotide sequences. Nucleic Acids Res., 15, 491-507.
35. Cai,L., Chen,L., Raghavan,S., Ratliff,R., Moyzis,R. and Rich,A. (1998) Intercalated cytosine motif and novel adenine clusters in the crystal structure of the Tetrahymena telomere. Nucleic Acids Res., 26, 4696-4705.
36. Chaires,J.B. (1990) Biophysical chemistry of the daunomycin-DNA interaction. Biophys Chem., 35, 191-202.
37. Chaires,J.B., Fox,K.R., Herrera,J.E., Britt,M. and Waring,M.J. (1987) Site and sequence specificity of the daunomycin-DNA interaction. Biochemistry, 26, 8227-8236.
38. Fox,K.R. and Waring,M.J. (1984) DNA structural variations produced by actinomycin and distamycin as revealed by DNAase I footprinting. Nucleic Acids Res., 12, 9271-9285.
39. Francis,R., West,C. and Friedman,S.H. (2001) Targeting telomerase via its key RNA/DNA heteroduplex. Bioorganic Chem., 29, 107-117.
40. Ren,J., Qu,X., Dattagupta,N. and Chaires,J.B. (2001) Molecular recognition of a RNA:DNA hybrid structure. J. Am. Chem. Soc., 123, 6742-6743.
41. West,C., Francis,R. and Friedman,S.H. (2001) Small molecule/nucleic acid affinity chromatography: Application for the identification of telomerase inhibitors which target its key RNA/DNA heteroduplex. Bioorg. Med. Chem. Lett., 11, 2727-2730.
42. Fritzsche,H. and Rupprecht,A. (1990) Modulation of the B-A transition of DNAby potential antitumor antibiotics. Influence of the base composition of DNA. J. Biomol. Struct. Dyn., 7, 1135-1140.
43. Zimmer,C., Marck,C. and Guschlbauer,W. (1983) Z-DNA and other non- B-DNA structures are reversed to B-DNA by interaction with netropsin. FEBS Lett., 154, 156-160.
44. Bailly,C., Colson,P., Houssier,C. and Hamy,F. (1996) The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism. Nucleic Acids Res., 24, 1460-1464.
45. De Moura,K.C., Salomao,K., Menna-Barreto,R.F., Emery,F.S., Pinto Mdo,C., Pinto,A.V. and de Castro,S.L. (2004) Studies on the trypanocidal activity of semi-synthetic pyran[b-4,3]naphtho[1,2-d]imidazoles from beta-lapachone. Eur. J. Med. Chem., 39, 639-645.
46. Plum,G.E. (2000) Optical Methods. In Beaucage,S.L., Bergstrom,D.E., Glick,G.D. and Jones,R.A. (eds.), Current Protocols in Nucleic Acid Chemistry. John Wiley & Sons, Inc., New York, Vol. 1, p. 7.3.1-7.3.17.